These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20568674)

  • 1. Polyomavirus BK neutralizing activity in human immunoglobulin preparations.
    Randhawa PS; Schonder K; Shapiro R; Farasati N; Huang Y
    Transplantation; 2010 Jun; 89(12):1462-5. PubMed ID: 20568674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients.
    Pastrana DV; Brennan DC; Cuburu N; Storch GA; Viscidi RP; Randhawa PS; Buck CB
    PLoS Pathog; 2012; 8(4):e1002650. PubMed ID: 22511874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients-Results from a proof-of-concept study.
    Benotmane I; Solis M; Velay A; Cognard N; Olagne J; Gautier Vargas G; Perrin P; Marx D; Soulier E; Gallais F; Moulin B; Fafi-Kremer S; Caillard S
    Am J Transplant; 2021 Jan; 21(1):329-337. PubMed ID: 32741096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients.
    Anyaegbu EI; Almond PS; Milligan T; Allen WR; Gharaybeh S; Al-Akash SI
    Pediatr Transplant; 2012 Feb; 16(1):E19-24. PubMed ID: 22248251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intravenous immunoglobulin therapy and Fc gamma receptor polymorphisms on BK virus nephropathy in kidney transplant recipients.
    Moon J; Chang Y; Shah T; Min DI
    Transpl Infect Dis; 2020 Aug; 22(4):e13300. PubMed ID: 32323406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive intravenous human immunoglobulin G suppresses BK polyomavirus replication and spread of infection in vitro.
    Sato N; Shiraki A; Mori KP; Sakai K; Takemura Y; Yanagita M; Imoto S; Tanabe K; Shiraki K
    Am J Transplant; 2024 May; 24(5):765-773. PubMed ID: 37977231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of BK Virus Neutralizing Serostatus With the Incidence of BK Viremia in Kidney Transplant Recipients.
    Abend JR; Changala M; Sathe A; Casey F; Kistler A; Chandran S; Howard A; Wojciechowski D
    Transplantation; 2017 Jun; 101(6):1495-1505. PubMed ID: 27854236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients.
    Vu D; Shah T; Ansari J; Naraghi R; Min D
    Transplant Proc; 2015 Mar; 47(2):394-8. PubMed ID: 25769580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab.
    Barbosa D; Kahwaji J; Puliyanda D; Mirocha J; Reinsmoen N; Lai CH; Villicana R; Peng A; Jordan SC; Vo A; Toyoda M
    Transplantation; 2014 Apr; 97(7):755-61. PubMed ID: 24686425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Dose Intravenous Immunoglobulin Treatment of Polyomavirus Nephropathy Developing After T Cell-Mediated Rejection Treatment: A Case Report.
    Hwang SD; Lee JH; Lee SW; Kim JK; Kim MJ; Song JH
    Transplant Proc; 2018 Oct; 50(8):2575-2578. PubMed ID: 29871774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Intravenous Immunoglobulin in the Treatment of Persistent BK Viremia and BK Virus Nephropathy in Renal Transplant Recipients.
    Shah T; Vu D; Naraghi R; Campbell A; Min D
    Clin Transpl; 2014; ():109-16. PubMed ID: 26281134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy.
    Solis M; Velay A; Porcher R; Domingo-Calap P; Soulier E; Joly M; Meddeb M; Kack-Kack W; Moulin B; Bahram S; Stoll-Keller F; Barth H; Caillard S; Fafi-Kremer S
    J Am Soc Nephrol; 2018 Jan; 29(1):326-334. PubMed ID: 29042457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral Origin, Clinical Course, and Renal Outcomes in Patients With BK Virus Infection After Living-Donor Renal Transplantation.
    Schwarz A; Linnenweber-Held S; Heim A; Framke T; Haller H; Schmitt C
    Transplantation; 2016 Apr; 100(4):844-53. PubMed ID: 26720302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction Between Human Polyomavirus BK and Hypoxia Inducible Factor-1 alpha.
    Signorini L; Croci M; Boldorini R; Varella RB; Elia F; Carluccio S; Villani S; Bella R; Ferrante P; Delbue S
    J Cell Physiol; 2016 Jun; 231(6):1343-9. PubMed ID: 26529465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK.
    Randhawa P; Pastrana DV; Zeng G; Huang Y; Shapiro R; Sood P; Puttarajappa C; Berger M; Hariharan S; Buck CB
    Am J Transplant; 2015 Apr; 15(4):1014-20. PubMed ID: 25736704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients.
    Gabardi S; Townsend K; Martin ST; Chandraker A
    Transpl Infect Dis; 2013 Aug; 15(4):361-8. PubMed ID: 23647907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of BK Polyomaviruses from Kidney Transplant Recipients Suggests a Role for APOBEC3 in Driving In-Host Virus Evolution.
    Peretti A; Geoghegan EM; Pastrana DV; Smola S; Feld P; Sauter M; Lohse S; Ramesh M; Lim ES; Wang D; Borgogna C; FitzGerald PC; Bliskovsky V; Starrett GJ; Law EK; Harris RS; Killian JK; Zhu J; Pineda M; Meltzer PS; Boldorini R; Gariglio M; Buck CB
    Cell Host Microbe; 2018 May; 23(5):628-635.e7. PubMed ID: 29746834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients.
    Velay A; Solis M; Benotmane I; Gantner P; Soulier E; Moulin B; Caillard S; Fafi-Kremer S
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches.
    Ginevri F; De Santis R; Comoli P; Pastorino N; Rossi C; Botti G; Fontana I; Nocera A; Cardillo M; Ciardi MR; Locatelli F; Maccario R; Perfumo F; Azzi A
    Transplantation; 2003 Apr; 75(8):1266-70. PubMed ID: 12717214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic diversity of polyomaviruses circulating among kidney transplant recipients in Kuwait.
    Chehadeh W; Nampoory MR
    J Med Virol; 2013 Sep; 85(9):1624-31. PubMed ID: 23775307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.